ReviewNature medicine2021
Looking beyond COVID-19 vaccine phase 3 trials.
Review in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 311 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
311 citing papers in PubMed, 2 syntheses or guidelines pooled it, 631 citations in OpenAlex.
- Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials.The Lancet. Microbe · 2023Pooled it
- The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.BMJ (Clinical research ed.) · 2023Trial
- Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result.Frontiers in immunology · 2023Trial
- Trial
- COVID-19 vaccine acceptance and rejection in an adult population in Bosnia and Herzegovina.PloS one · 2022Trial
- The effectiveness of COVID-19 vaccines and the added benefit of booster doses in Hessen, Germany, during the COVID-19 pandemic: Results from a vaccinated-only study.Human vaccines & immunotherapeutics · 2026Article
- Observational
- Exploring vaccine acceptance using Protection Motivation Theory: A study of college students' behavioral intentions in the context of COVID-19.Human vaccines & immunotherapeutics · 2025Article
- Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.Vaccines · 2025Review
- Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.Molecular therapy. Nucleic acids · 2025Review
- Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance.Frontiers in medicine · 2025Article
- Discovery of Novel Natural Inhibitors against SARS-CoV-2 Main Protease: A Rational Approach to Antiviral Therapeutics.Current medicinal chemistry · 2025Article
- Safety and efficiency of COVID-19 vaccine in North Africa.Human vaccines & immunotherapeutics · 2024Article
- Article
- Psychosocial Factors Inhibiting Timely COVID-19 Vaccination and Booster Receipt Among Transgender and Gender Diverse Adults.Transgender health · 2024Article
- Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.Journal of virology · 2024Article
- A vaccination-based COVID-19 model: Analysis and prediction using Hamiltonian Monte Carlo.Heliyon · 2024Article
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
251 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required. These considerations should include how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, the equitable distribution of vaccines and the logistics of global vaccine delivery, all of which are a prelude to a massive vaccination campaign targeting people of all ages. Furthermore, additional scientific questions about the vaccines remain that should be answered to improve vaccine efficacy, including questions regarding the optimization of vaccination regimens, booster doses, the correlates of protection, vaccine effectiveness, safety and enhanced surveillance. The timely and coordinated execution of these post-efficacy tasks will bring the pandemic to an effective, and efficient, close.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.